EU CBD regulation remains one of the biggest barriers to growth in the CBD Europe market. Although demand for CBD products continues to rise, CBD food supplements and ingestible products still face major hurdles under the EU novel food framework, with EFSA and the European Commission maintaining a cautious position on safety and approval and no full EU authorization yet granted.
Across Europe, businesses face a patchwork of national enforcement, uncertain approval timelines, and growing pressure to align products with evolving safety expectations.
At the same time, EFSA has advanced its scientific evaluation by setting a provisional intake level for cannabidiol of approximately 2 mg/day for a 70 kg adult, while also highlighting persistent data gaps that continue to prevent full approval under the EU novel food framework.
In this blog, we cover:
- The evolving opportunity in the CBD industry in Europe
- Key regulatory barriers under EU CBD regulation
- The latest 2026 EFSA CBD approval developments
- Strategic implications for industry and clinical research
Table of Contents
The CBD Europe Market Opportunity
Consumer interest in CBD has grown exponentially in recent years, driven by a broader demand for wellness-oriented, functional ingredients. CBD is now widely associated with lifestyle benefits such as stress management, sleep support, and recovery.
Product innovation has followed this trend, with offerings across:
- Gummies and confectionery
- Oils and tinctures
- Functional beverages
- Skincare and topical applications
Across Europe, CBD products remain widely available despite regulatory complexity, reflecting strong consumer demand. However, the market is defined by a contradiction: high consumer uptake alongside cautious retail expansion. Uncertain compliance requirements and enforcement risks – particularly for ingestible products under novel food legislation – continue to hold the sector back.
What Is Holding Back the CBD Market in Europe?
Why CBD Novel Food Approval Is Delayed in the EU
CBD is classified as a novel food under Regulation (EU) 2015/2283, which means it requires pre-authorisation before it can be marketed as a food or supplement. However, no CBD ingredient or product has yet been fully authorised in the EU, and severalCBD novel food applications remain under evaluation, with no full EU authorisation yet granted due to the critical data gaps identified by EFSA. This has created a legal bottleneck for the entire ingestible CBD market.
EFSA’s CBD Safety Review and Why It Matters
EFSA has identified critical gaps in the scientific evidence base, including potential effects on liver function, the endocrine system, and reproductive health.
As a result, assessments have slowed or paused pending additional data, with only a provisional safe intake level of approximately 2 mg/day for a 70 kg adult established so far. This precautionary stance reflects the EU’s risk-averse regulatory approach, but it also continues to delay product availability.
Why CBD Rules Differ Across Europe?
Despite the existence of EU-level rules and frameworks, implementation remains inconsistent:
Some countries tolerate CBD products under limited conditions, while others are tightening enforcement. THC limits and permitted product formats also vary nationally. This fragmentation creates legal uncertainty for manufacturers, barriers to cross-border trade, and greater compliance complexity across the EU.
Latest EFSA CBD Update for 2026
While challenges remain, 2026 has brought a few important signs of progress:
- EFSA has published an updated provisional safety threshold, providing at least a partial scientific reference point.
- Ongoing engagement with applicants suggests that the novel food process is still moving forward.
- Increased regulatory scrutiny may ultimately support the market’s long-term legitimacy.
However, it is important to note:
- These developments do not yet equate to authorisation
- The pathway to approval remains uncertain and data-intensive
How EU CBD Regulation Affects Businesses?
1. Slower Innovation
Companies face delays in launching ingestible products due to unclear approval timelines and evolving regulatory requirements.
2. Reduced Investment
Regulatory uncertainty continues to weigh on investor confidence, with funding often redirected to less complex categories such as cosmetics.
3. Limited Consumer Access
Consumers can access CBD products, but:
Product availability is inconsistent
Many offerings exist in a legal grey area rather than a fully authorized framework
4. Higher Compliance Costs
Businesses must invest heavily in:
- Toxicological data
- Stability studies
- Manufacturing controls
- Regulatory documentation
How the UK and Switzerland Compare With the EU?
Compared with the EU, some markets have adopted more pragmatic approaches:
United Kingdom
- CBD is legal if it complies with safety requirements and THC thresholds.
- The Food Standards Agency (FSA) has created a public list of products linked to valid novel food applications, allowing continued market access during review.
Switzerland
- Switzerland operates outside the EU novel food framework.
- Applying a separate legal framework, including distinct THC thresholds under Swiss law, but CBD foods and hemp extracts may still be treated as novel foods depending on their composition and history of use.
What the EU CBD Market Needs to Grow
For Europe’s CBD market to mature, a few things need to happen first:
- A more joined-up approach to enforcement across EU countries
- Clearer, science-backed guidance on safe doses
- More consistent quality and testing standards right across the supply chain
Without these developments, the market risks ongoing fragmentation and slower growth.
Why Clinical Research Matters for CBD Approval
The current regulatory landscape highlights a clear opportunity: high-quality scientific evidence remains the missing link.
Key areas where research can support regulatory progress include:
- Human safety studies to address EFSA data gaps
- Tolerability and pharmacokinetic research
- Consumer perception and usage studies
- Functional ingredient evidence generation
- Claims substantiation aligned with regulatory expectations
At Atlantia Clinical Trials, we support the generation of robust clinical evidence for novel ingredients, including CBD. That includes designing and conducting studies aligned with EFSA and FSA expectations, helping to bridge the gap between innovation and regulatory approval.
Final Thoughts on EU CBD Regulation
CBD remains one of the most promising yet complex ingredient categories in Europe today. While consumer demand and commercial potential are clear, regulatory frameworks have struggled to keep pace.
The coming years will be defined by:
- Whether safety data can be produced to meet regulatory expectations
- How quickly authorisation pathways can be clarified
Until then, CBD in Europe will remain a high-potential market operating under regulatory constraint.
FAQs on CBD Regulation in Europe
Is CBD legal in the EU?
CBD itself is not treated as a narcotic under EU case law, however, CBD in food and supplements requires novel food authorisation, which has not yet been granted.
Why is CBD considered a novel food in the EU?
CBD extracts were not consumed significantly in the EU before May 1997, so they fall under the EU’s novel food regulation requiring pre-market approval.
Has any CBD food product been approved in the EU?
No, as of 2026, no CBD food or supplement has received full EU novel food authorisation.
Will EU CBD regulation change in 2026?
There are signs of progress, including updated EFSA safety guidance, but timelines for full authorisation remain uncertain and depend on additional scientific data.